Nature Communications (Feb 2022)

A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase

  • Ashleigh Shannon,
  • Véronique Fattorini,
  • Bhawna Sama,
  • Barbara Selisko,
  • Mikael Feracci,
  • Camille Falcou,
  • Pierre Gauffre,
  • Priscila El Kazzi,
  • Adrien Delpal,
  • Etienne Decroly,
  • Karine Alvarez,
  • Cécilia Eydoux,
  • Jean-Claude Guillemot,
  • Adel Moussa,
  • Steven S. Good,
  • Paolo La Colla,
  • Kai Lin,
  • Jean-Pierre Sommadossi,
  • Yingxiao Zhu,
  • Xiaodong Yan,
  • Hui Shi,
  • François Ferron,
  • Bruno Canard

DOI
https://doi.org/10.1038/s41467-022-28113-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

The drug AT-527 targets the SARS-CoV-2 replication machinery. Here the authors use Cryo-EM to show how AT-527 inhibits SARS-CoV-2 polymerase by acting as an immediate RNA chain terminator and stably binding in a NiRAN active-site pocket; impeding an essential nucleotide-transfer activity.